Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13548371 | 0.87 | OPRM1 (0.60) | OPRM1ACHESIGMAR1 | |
| SCHEMBL18425484 | 0.86 | OPRM1 (0.50) | OPRM1ACHECCR3CHRM4SIGMAR1 | |
| SCHEMBL19615075 | 0.78 | ACHE (0.47) | OPRM1ACHECCR3CHRM4SIGMAR1 | |
| SCHEMBL19631869 | 0.78 | OPRM1 (0.44) | OPRM1ACHECCR3CHRM4SIGMAR1 | |
| SCHEMBL19631651 | 0.78 | ACHE (0.47) | OPRM1ACHECCR3CHRM4SIGMAR1 | |
| SCHEMBL7625330 | 0.76 | ACHE (0.50) | ACHECCR3SIGMAR1DRD2DRD4 | |
| SCHEMBL5199646 | 0.74 | OPRM1 (0.55) | OPRM1SIGMAR1HRH3DRD4TMEM97 | |
| SCHEMBL6608253 | 0.74 | OPRM1 (0.55) | OPRM1SIGMAR1DRD4TMEM97 | |
| SCHEMBL14836350 | 0.74 | OPRM1 (0.55) | OPRM1SIGMAR1HRH3DRD4TMEM97 | |
| SCHEMBL2988825 | 0.73 | MEN1 (0.55) | ACHECCR3SIGMAR1DPP7DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | OPRM1 42/4885ACHE 2188/4885CCR3 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.